Brief: Kyowa Kirin And MEI Pharma Announce Topline Data From Phase 2 MIRAGE Study Evaluating Zandelisib In Patients With Indolent B-Cell Non-Hodgkin's Lymphoma In Japan
18/11/2022 13:12
Nov 18 (Reuters) - Kyowa Kirin Co Ltd 4151.T :
* KYOWA KIRIN AND MEI PHARMA ANNOUNCE TOPLINE DATA FROM
PHASE 2
MIRAGE STUDY EVALUATING ZANDELISIB IN PATIENTS WITH INDOLENT
B-CELL NON-HODGKIN'S LYMPHOMA IN JAPAN
* MEI PHARMA INC - INTERIM DATA FROM PHASE II STUDY OF
ZANDELISIB
SHOWS 75.4% ORR IN JAPANESE PATIENTS WITH INDOLENT B-CELL NHL
* MEI PHARMA INC - WITH 9.5 MONTHS MEDIAN DURATION OF
FOLLOW-UP, A
DISCONTINUATION RATE DUE TO ANY TREATMENT EMERGENT ADVERSE EVENT
WAS 14.8%
Source text for Eikon: ID:nBw6xglCa
Further company coverage: 4151.T
Recent news on Lite Strategy
See all newsBrief: Lite Strategy Receives Governance Rights And Option To Buy Litvm Future Network Tokens
U.S. RESEARCH ROUNDUP- Equinix, KLA, WW Grainger
Brief: Lite Strategy Inc - On Nov 14, Board Approves Justin J. File As Permanent CEO - SEC Filing
Brief: Lite Strategy Reports First Quarter Fiscal Year 2026 Results Highlights Successful Launch Of $100M Litecoin Treasury Strategy And Movement Into Active Capital Market Operations
Brief: Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation To Active Capital Market Operations